Accession Number: | 0001735276-19-000083 |
Date: | 2019-08-06 |
Issuer: | ALNYLAM PHARMACEUTICALS, INC. (ALNY) |
Original Submission Date: |
MARAGANORE JOHN
300 THIRD STREET
CAMBRIDGE, MA 02142
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2019-07-11 | J | 34 | a | $0.00 | 3,133 | indirect | f1 | |
COMMON STOCK | 2019-08-06 | 0 | $0.00 | 189,993 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
PERFORMANCE STOCK OPTION 2015 (RIGHT TO BUY) | 88.95 | 2019-08-06 | deemed execution date | A | 16,250 (a) | 2019-08-06 | 2025-12-18 | common stock 16,250 | $88.95 | 65,000 | direct | |
PERFORMANCE STOCK OPTION 2016 (RIGHT TO BUY) | 42.22 | 2019-08-06 | deemed execution date | A | 6,250 (a) | 2019-08-06 | 2026-12-20 | common stock 6,250 | $42.22 | 25,000 | direct |
ID | footnote |
---|---|
f1 | reflects shares of alny common stock acquired by the reporting person under the alny 401(k) plan as a result of the alny 401(k) matching contribution program. |
f2 | on december 18, 2015, the reporting person was granted a performance based stock option to purchase shares of alny common stock. one quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. the compensation committee of the company determined that the fourth performance criterion was met effective as of august 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. |
f3 | on december 20, 2016, the reporting person was granted a performance based stock option to purchase shares of alny common stock. one quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. the compensation committee of the company determined that the fourth performance criterion was met effective as of august 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. |